Autologous bone marrow transplantation in acute leukemia and lymphoma following ex vivo treatment with monoclonal antibodies and complement.
Freedman
A S
AS
Takvorian
T
T
Nadler
L M
LM
Anderson
K C
KC
Sallan
S E
SE
Ritz
J
J
D000208:Acute Disease; D000328:Adult; D000911:Antibodies, Monoclonal / Q000276:immunology*; D000912:Antibodies, Neoplasm / Q000276:immunology*; D000943:Antigens, Differentiation / Q000276:immunology; D000951:Antigens, Neoplasm / Q000276:immunology; D001853:Bone Marrow / Q000473:pathology; D016026:Bone Marrow Transplantation; D002648:Child; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D003165:Complement System Proteins / Q000276:immunology*; D006412:Hematopoietic Stem Cells / Q000276:immunology; D006801:Humans; D000922:Immunotoxins / Q000494:pharmacology / Q000627:therapeutic use; D007938:Leukemia / Q000276:immunology / Q000473:pathology / Q000601:surgery* / Q000628:therapy; D008212:Lymphocyte Depletion; D008214:Lymphocytes / Q000276:immunology; D008228:Lymphoma, Non-Hodgkin / Q000276:immunology / Q000473:pathology / Q000601:surgery* / Q000628:therapy; D014411:Neoplastic Stem Cells / Q000187:drug effects / Q000276:immunology / Q000473:pathology*; D014182:Transplantation, Autologous
D000911:Antibodies, Monoclonal; D000912:Antibodies, Neoplasm; D000943:Antigens, Differentiation; D000951:Antigens, Neoplasm; D000922:Immunotoxins; D003165:Complement System Proteins